NASDAQ · CTNM
Healthcare · Biotechnology
$12.72
Down-$0.07 (-0.55%)
Updated Oct 6, 2026, 10:00 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTNM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CTNM closed at $12.72 after 20 trading sessions, down 20.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $13.14 | $13.295 | $12.41 | $12.72 | 508.4K |
| Oct 2, 2026 | $13.15 | $13.24 | $12.585 | $13.12 | 794.26K |
| Oct 1, 2026 | $13.30 | $13.50 | $12.62 | $12.99 | 773.99K |
| Sep 30, 2026 | $11.59 | $13.545 | $11.59 | $13.42 | 1.6M |
| Sep 29, 2026 | $12.83 | $13.085 | $10.84 | $11.50 | 856.27K |
| Sep 28, 2026 | $12.38 | $13.36 | $11.95 | $12.73 | 534.13K |
| Sep 25, 2026 | $12.57 | $12.88 | $12.10 | $12.56 | 404.93K |
| Sep 24, 2026 | $12.49 | $12.74 | $11.40 | $12.49 | 632.16K |
| Sep 23, 2026 | $13.33 | $13.33 | $12.44 | $12.51 | 550.26K |
| Sep 22, 2026 | $13.74 | $14.00 | $13.19 | $13.40 | 770.3K |
| Sep 21, 2026 | $13.69 | $13.89 | $13.4401 | $13.55 | 638.48K |
| Sep 18, 2026 | $13.23 | $13.89 | $13.145 | $13.53 | 2.14M |
| Sep 17, 2026 | $14.07 | $14.40 | $12.86 | $13.21 | 580.1K |
| Sep 16, 2026 | $13.97 | $14.595 | $13.70 | $13.76 | 785.96K |
| Sep 15, 2026 | $13.76 | $14.18 | $13.08 | $13.82 | 704.61K |
| Sep 14, 2026 | $14.89 | $15.51 | $14.74 | $14.82 | 608.39K |
| Sep 11, 2026 | $14.94 | $15.235 | $14.62 | $14.82 | 165.14K |
| Sep 10, 2026 | $14.97 | $15.22 | $14.61 | $14.66 | 203.29K |
| Sep 9, 2026 | $15.81 | $16.06 | $15.09 | $15.14 | 388.83K |
| Sep 8, 2026 | $16.59 | $16.95 | $15.88 | $15.94 | 316.18K |
The latest Smart Investors Daily articles mentioning CTNM.
Company
Market Activity
Research & News
CTNM research
Company profile and research snapshot.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 15, 2026 | Jones Trading | Buy | — |
| Sep 15, 2026 | Baird | Outperform | — |
| Jul 31, 2026 | RBC Capital | Outperform | — |
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-Weight and lowers the price target from $18 to $17.
Yahoo · Sep 24, 2026
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]
Yahoo · Sep 15, 2026
Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S
Yahoo · Sep 15, 2026
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTNM.
